Investment firm Giverny Capital Asset Management reduced its stake in industrial manufacturer AMETEK in Q4 2025, highlighting a disciplined approach to valuation as markets remain captivated by AI narratives. The firm's portfolio underperformed major indices, pressured by its underweight stance in mega-cap technology.
Amid a sluggish housing sector, Installed Building Products (IBP) has demonstrated remarkable resilience, becoming a standout performer in Giverny Capital's portfolio. The insulation specialist's shares have surged over 50% in the past year, bucking broader market trends.
Despite a challenging 2025, Giverny Capital's latest investor letter highlights Charles Schwab as a key portfolio contributor, projecting sustained growth for the financial giant as market dynamics evolve.
As markets face significant pressure, certain portfolios tied to strategic commodities, resilient tech, and innovative crypto infrastructure are showing notable resilience. Analysts point to long-term thematic bets that are weathering the current storm.
For those on a fixed income, inflation isn't just an economic indicator—it's a direct assault on financial security. Experts warn that failing to plan for rising costs can halve a retiree's purchasing power over decades. Here’s a strategic guide to building a resilient portfolio.
BeOne Medicines extends its collaboration with quantitative systems pharmacology firm InSysBio, aiming to optimize clinical trial dosing and mitigate cytokine release syndrome risks across its broad portfolio of 15 novel oncology assets.
Jim Saulnier & Associates reduced its position in the Vanguard 0-3 Month T-Bill ETF by over $5.8 million in Q4, yet short-term Treasuries remain a key liquidity component, accounting for over 5% of its portfolio.
While low-volatility stocks can anchor a portfolio, investors often sacrifice growth for safety. We analyze one steady performer with durable advantages and two companies where challenges may outweigh the stability premium.
As markets navigate uncertainty, a low-cost, diversified bond ETF is gaining renewed attention from investors seeking stable yield and portfolio ballast. We examine the strategy behind one popular fund and its role in a long-term income plan.
In the quarters leading to his retirement as CEO, Warren Buffett orchestrated a significant portfolio shift, slashing Berkshire's stake in Bank of America while steadily accumulating shares in Domino's Pizza, highlighting a strategic bet on consumer resilience and brand loyalty.
Roth Capital has upgraded Energy Fuels (UUUU) from 'Sell' to 'Neutral', raising its price target to $15. The move follows the uranium miner's strategic acquisition of Australian Strategic Materials, expanding its rare earths portfolio and positioning within Western critical mineral supply chains.
At 77, Jane Perry's £2 million ISA portfolio stands as a testament to a simple, disciplined investment strategy begun in the 1980s. Her story challenges the gender investment gap and offers a blueprint for long-term wealth building.
Orchid Island Capital, Inc. (NYSE:ORC) reported a dramatic surge in full-year 2025 net income, driven by a strategic expansion of its agency MBS portfolio and disciplined hedging. The results mark a potential inflection point for the mortgage REIT, reshaping its risk-reward profile after years of uneven performance.
A significant purchase of the Invesco BulletShares 2027 Corporate Bond ETF by BCS Wealth Management highlights a strategic move to build predictable cash flows within a multi-year portfolio, emphasizing capital preservation over speculative yield chasing.
As Amgen prepares to release its fourth-quarter results, investors are watching for signs of sustained momentum in its key drug portfolios and the impact of recent acquisitions.
As Pfizer prepares to report its fourth-quarter results, investors are weighing the company's strategic pivot beyond its COVID-19 portfolio against a backdrop of expected revenue declines. The report may set the tone for the broader pharmaceutical sector.
The 179-year-old tobacco giant Philip Morris International is closing its Richmond, Virginia office, eliminating 135 positions, as it aggressively restructures around its smoke-free product portfolio, led by the ZYN nicotine pouch brand.
Bayer's share price has more than doubled in the past 12 months, yet key valuation models suggest a significant gap remains between its market price and intrinsic value. We examine the metrics behind the rally and the lingering legal and portfolio challenges facing the company.
Investment firm Tanager Wealth Management has fully divested its position in Centessa Pharmaceuticals, capitalizing on the biotech's near-60% annual surge. The move highlights strategic portfolio rebalancing as the stock's rally potentially amplified its risk profile within a diversified fund.
While both ETFs target the high-flying U.S. technology sector, a closer look reveals critical distinctions in diversification, concentration risk, and liquidity that could sway long-term portfolio outcomes.
